




RealRate

PHARMACEUTICAL 2020

Seres Therapeutics Inc.
Rank 201 of 362



RealRate

• Financial Strength Rankings using Artificial Intelligence • www.realrate.ai



PHARMACEUTICAL 2020

Seres Therapeutics Inc.
Rank 201 of 362



The relative strengths and weaknesses of Seres Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Seres Therapeutics Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 46% points. The greatest weakness of Seres Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 67% points.

The company's Economic Capital Ratio, given in the ranking table, is -216%, being 87% points above the market average of -303%.

| Input Variable | Value in 1000 USD |
|---|-------------------|
| Assets, Current | 100,189 |
| Cost of Goods Sold | 0 |
| Intangible Assets | 0 |
| Liabilities, Current | 45,993 |
| Liabilities, Non-Current | 21,012 |
| Other Assets | 12,756 |
| Other Compr. Net Income | 0 |
| Other Expenses | 1,492 |
| Other Liabilities | 113,759 |
| Other Net Income | 1,597 |
| Property and Equipment | 19,495 |
| Research and Development | 80,141 |
| Revenues | 34,505 |
| Selling, General and Administrative Expense | 24,748 |

| Output Variable | Value in 1000 USD |
|--------------------------|-------------------|
| Assets | 132,440 |
| Liabilities | 180,764 |
| Expenses | 106,381 |
| Stockholders Equity | -48,324 |
| Net Income | -70,279 |
| Comprehensive Net Income | -70,279 |
| Economic Capital Ratio | -216% |

